Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply

Kristin K. Jørgensen, Knut E. Lundin, Inge C. Olsen, Tore K. Kvien, Jørgen Jahnsen
December, 2017
Cite DOI
Type
Journal article
Publication
Lancet (London, England)
Humans Treatment Outcome Infliximab Antibodies Monoclonal Biosimilar Pharmaceuticals Gastrointestinal Agents Azathioprine Crohn Disease Mercaptopurine